Through the discovery http://www.vigora.biz.

Through the discovery, development and commercialization of new drugs, Takeda is a leader in acid – related therapy for more than 15 years and goal goal of new therapies to market, said Alan MacKenzie, president and CEO, Takeda Pharmaceuticals North America. KAPIDEX is a new, innovative treatment option with proven PPI market. http://www.vigora.biz here .

The White Paper notes a company is related to the development of dozens of chronic – and costly diseases – to nearly 75 % of health spending. More more, obesity has doubled over the past two decades, nearly 30 % of the increase in healthcare spending in the country has seen in that time.

follow this web-site

Certain statements in this Pressemitteilung are forward-looking within the meaning of of Private Litigation Reform Act of 1995. These statements are by the use of forward-looking words such as anticipate, believe, forecast, estimates and want to among others. These forward looking statements are based on current expected VIVUS ‘ and actual results could differ materially. There are a number by factors that may cause such forward differ materially from those in such forward – looking statements. These factors include, but are not limited to, significant competition confined; uncertainties patent protection and litigation, uncertainties the government and third payer refunds, trusting in the sole source supplier, limited sales and marketing endeavors and reliance on third parties, forward looking statements which developing innovative products and risks linked to non-compliance with with FDA release or permits and receive non-compliance with FDA. Like in any other pharmaceutical in the development of, there are significant risks in which development, regulatory approval and marketing new products. There no guarantee that future clinical studies discussed above contained in this release closed themes or will be successful and each product be for any indication for any indication or prove commercially successful. VIVUS assumes no obligation an undertaking to update or revise forward-looking statements. Investors should read the risk factor, the 31 in VIVUS ‘Form 10-K for the year ended December 2008 periodic reports filed with the Securities and Exchange Commission filings has been filed.

Published by